Artidis joins world’s largest medical center
The Basel-based startup Artidis is developing a medical device based on nanotechnology to help with cancer diagnoses. The spin-off from the University of Basel has now been successfully integrated in the Texas Medical Center and will therefore have access to the US market.
The team of Artidis, a spin off from the University of Basel (Photo: Artidis)
In a press release, the University of Basel describes the Texas Medical Center (TMC) as the “world’s largest medical center”. Its capacities in the life sciences sector are complemented by the expertise of companies that qualify for the TMC Innovation Accelerator. This year, a total of 140 startups applied to join the international cohort of medical devices, with 16 ultimately proving successful. Artidis, a spin-off from the University of Basel, was one of the successful applicants.
Artidis, which was formed from a research group comprising the University of Basel and the Swiss Nanoscience Institute, has used its proprietary nanotechnology platform in order to develop “the first nanomechanical biomarker for cancer diagnosis and treatment optimization”. The platform integrates different types of clinical data, allowing current diagnostic processes to be shortened and personalized plans for cancer treatment to be produced. As part of the TMC, Artidis can now launch this technology on the US market. “Being part of the TMC Innovation Accelerator program is a great opportunity for us as it provides access to a unique environment at the forefront of science and innovation – the best place to take patient care to the next level”, says Marija Plodinec, CEO of Artidis, in the press release.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More